References
- Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, . Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. NEJM 2007;356:2271–81.
- Motzer RJ, Escudier B, Oudasrd S, . Efficacy of ever-olimus in advanced renal cell carcinoma: A double-blind, randomized, placebo-controlled phase III trial. Lancet 2008; 372(9637):449–56.
- Stallone G, Infante B, Di Paolo S, . Sirolimus and angiotensin-converting enzyme inhibitors together induce tongue oedema in renal transplant recipients. Nephrol Dial Transplant 2004;19:2906–8.
- Fuchs U, Zittermann A, Berthold KH, . Immunosuppressive therapy with everolimus can be associated with potentially life-threatening lingual angioedema. Transplantation 2006;79:981–3.
- Wadei H, Gruber SA, El-Amm JM, . Sirolimus-induced angioedema. Am J Transplant 2004;4:1002–5.
- Mahe E, Morelon E, Lechaton S. Angioedema in renal translplant recipients on sirolimus. Dermatology 2007;214: 205–9.
- Rothenburger M, Zuckermann A, Bara C, . Recommendations for the use of everolimus (certican) in heart transplantation: Results from the Second German-Austrian Certican Consensus Conference. J Heart Lung Transplant 2007;26:305–11.
- Wyeth. Prescribing Information for Torisel: September 2008; Http://www.wyeth.com/content/showlabeling.asp?id =490, p 11.
- Novartis. Prescribing Information for Afinitor: March 2009; http:// www.pharma.us.novartis.com/product/pi/pdf/afi nitor.pdf, p 2.